A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
- Study Title
- A Phase 1b, Open-Label Trial to Assess Safety and Efficacy of TEV-53408 in Participants With Vitiligo
- Teva Identifier
- TV53408-IMM-10209
- ClinicalTrials.gov Identifier
- NCT06625177
- Study Status
- Recruiting
- Trial Condition(s)
- Vitiligo
- Interventions
- Drug: TEV-53408
- Study Description
- Primary objectives: The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. Another primary objective is to evaluate the efficacy of TEV-53408. Secondary objectives: A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 75 Years
- Trial Duration
- November 11, 2024 - June 05, 2027
- Phase
- Phase 1
